Neosync ranked #30 Holder of Pervasive Neurotech Intellectual Property*

By SharpBrains | August 19, 2015 |

Neo­sync is an ear­ly stage com­pa­ny devel­op­ing a new treat­ment  for major depres­sion based on Tran­scra­nial Mag­net­ic Stim­u­la­tion (TMS). The treatment–named NEST (Neo­sync EEG Syn­chro­nized TMS) and under­go­ing clin­i­cal trials–is based on the idea that depres­sion patients tend to have over­ly rhyth­mic brain activity, 

Read More

Upcoming market report on Pervasive Neurotechnology

By Alvaro Fernandez | March 2, 2015

Just a quick heads-up to the Sharp­Brains com­mu­ni­ty: we are wrap­ping up a com­pre­hen­sive mar­ket report on Per­va­sive Neu­rotech­nolo­gies (non-inva­­sive, scal­able, poten­tial­ly ubiq­ui­tous). To learn when it becomes avail­able, keep tuned via our e‑Newsletter. See below, in alpha­bet­i­cal order, a few of the orga­ni­za­tions to be pro­filed in the report, giv­en their rel­e­vant intel­lec­tu­al prop­er­ty portfolios…

Read More